These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17219761)

  • 41. Enfuvirtide, the first fusion inhibitor to treat HIV infection.
    Poveda E; Briz V; Soriano V
    AIDS Rev; 2005; 7(3):139-47. PubMed ID: 16302461
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparisons of methods for analysis of repeated binary responses with missing data.
    Frank Liu G; Zhan X
    J Biopharm Stat; 2011 May; 21(3):371-92. PubMed ID: 21442514
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [New drug class blocks virus-cell fusion. HIV not admitted].
    MMW Fortschr Med; 2003 Sep; 145(35-36):53. PubMed ID: 14584215
    [No Abstract]   [Full Text] [Related]  

  • 45. [Combined treatment with fusion inhibitor. HIV-1 viruses under control longer].
    MMW Fortschr Med; 2004 Apr; 146(15):68. PubMed ID: 15373030
    [No Abstract]   [Full Text] [Related]  

  • 46. Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy.
    Melby TE; Despirito M; Demasi RA; Heilek G; Thommes JA; Greenberg ML; Graham N
    AIDS; 2007 Nov; 21(18):2537-9. PubMed ID: 18025893
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1.
    Pérez-Alvarez L; Carmona R; Ocampo A; Asorey A; Miralles C; Pérez de Castro S; Pinilla M; Contreras G; Taboada JA; Nájera R
    J Med Virol; 2006 Feb; 78(2):141-7. PubMed ID: 16372284
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients.
    de Requena DG; Bonora S; Castagna A; Hasson H; Marucco DA; D'Avolio A; Sciandra M; Trentini L; Calcagno A; Lazzarin A; Di Perri G
    J Antimicrob Chemother; 2008 Aug; 62(2):384-7. PubMed ID: 18487231
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks.
    Sayana S; Prosser P; Ricaurte JC; Sanchez S; Hamwi G; Hershey-Weber J; Chien C; Easley A; Nguyen T; Wilson L; Khanlou H
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(2):85-6. PubMed ID: 19369697
    [No Abstract]   [Full Text] [Related]  

  • 50. MMRM versus MI in dealing with missing data--a comparison based on 25 NDA data sets.
    Siddiqui O
    J Biopharm Stat; 2011 May; 21(3):423-36. PubMed ID: 21442517
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discontinuation of the clinical development of fusion inhibitor T-1249.
    Martin-Carbonero L
    AIDS Rev; 2004; 6(1):61. PubMed ID: 15168742
    [No Abstract]   [Full Text] [Related]  

  • 52. Analyzing weight loss intervention studies with missing data: which methods should be used?
    Batterham MJ; Tapsell LC; Charlton KE
    Nutrition; 2013; 29(7-8):1024-9. PubMed ID: 23644010
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A multiple-imputation-based approach to sensitivity analyses and effectiveness assessments in longitudinal clinical trials.
    Ayele BT; Lipkovich I; Molenberghs G; Mallinckrodt CH
    J Biopharm Stat; 2014; 24(2):211-28. PubMed ID: 24605966
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Missing CD4+ cell response in randomized clinical trials of maraviroc and dolutegravir.
    Cuffe R; Barnett C; Granier C; Machida M; Wang C; Roger J
    HIV Clin Trials; 2015 Oct; 16(5):170-7. PubMed ID: 26365498
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multiple imputation: dealing with missing data.
    de Goeij MC; van Diepen M; Jager KJ; Tripepi G; Zoccali C; Dekker FW
    Nephrol Dial Transplant; 2013 Oct; 28(10):2415-20. PubMed ID: 23729490
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Estimating the effect of multiple imputation on incomplete longitudinal data with application to a randomized clinical study.
    Fong DY; Rai SN; Lam KS
    J Biopharm Stat; 2013; 23(5):1004-22. PubMed ID: 23957512
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intent-to-treat analysis for longitudinal clinical trials: coping with the challenge of missing values.
    Mazumdar S; Liu KS; Houck PR; Reynolds CF
    J Psychiatr Res; 1999; 33(2):87-95. PubMed ID: 10221740
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An evaluation of the trimmed mean approach in clinical trials with dropout.
    Wang MD; Liu J; Molenberghs G; Mallinckrodt C
    Pharm Stat; 2018 May; 17(3):278-289. PubMed ID: 29624854
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Using multiple imputation to estimate cumulative distribution functions in longitudinal data analysis with data missing at random.
    Dinh P
    Pharm Stat; 2013; 12(5):260-7. PubMed ID: 24019202
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Partial imputation approach to analysis of repeated measurements with dependent drop-outs.
    Wei L; Shih WJ
    Stat Med; 2001 Apr; 20(8):1197-214. PubMed ID: 11304736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.